Oblenio Bio
obleniobio.com
Actively hiring
Immunology & Inflammation Therapeutics
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$62M
1 round on record
Latest round
$62M
Series B · Jun 2026 · 3 mo ago
Team
51-200
employees, estimated range
Backers
1
Aditum Bio
The money's age
Fresh money
3 months since the last round · not hiring
Momentum
20/100
fresh money
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jun 24
Raised a round Series B $62M
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series B | Jun 2026 | $62M | — | streetinsider.com |
Registers and programsofficial lists and records that name the company
| Legal entity | Oblenio Bio Inc. | its site |
Backed byfrom the funds' portfolios and accelerator catalogs
Aditum Bio Similar startupsby what they do, their industry and backers
Ditto Bio discovers drugs for autoimmune diseases by harnessing parasite biology.
Coultreon Biopharma is a clinical-stage biotech company developing next-generation precision medicines for immunology and autoimmune…
A biotech company developing better medicines for patients with autoimmune and inflammatory diseases. Leveraging powerful insights into the…
SFA Therapeutics is developing a next-generation oral immune tolerance therapy for psoriasis. Our investigational approach is designed to…
On a mission to transform the future of autoimmune care. Developing innovative therapies with the potential to redefine the standard of…
Quell Therapeutics is a clinical-stage company, fuelled by curiosity and discovery, on a mission to make life better for those battling…
Overview
Oblenio Bio is pursuing broad immune reset as a transformative therapy for refractory autoimmune diseases through our LBL-051 T-cell engager.
News
Oblenio Bio Raises $62 Million Series B To Advance Autoimmune Disease Therapy
Oblenio Bio announced that it has closed an oversubscribed $62 million Series B financing round to advance its lead autoimmune disease program into clinical development. The round was led by Pfizer Ventures, with participation from new investors Deep Trac
Read more
Report
Oblenio Bio Closes $62 Million Series B to Advance Tri-specific T-Cell Engager LBL-051 for Autoimmune Diseases into Clinical Development
-- Round led by Pfizer Ventures, with participation from Deep Track Capital, GV, and founding investor, Aditum Bio -- --LBL-051's ability to reset the immune system is supported by recent preclinical data presented at EULAR 2026 -- Cambridge, Mass., June
Read more
Report
Oblenio Bio Closes $62 Million Series B To Advance Tri-Specific T-Cell Engager LBL-051 For Autoimmune Diseases Into Clinical Development
Oblenio Bio Closes $62 Million Series B To Advance Tri-Specific T-Cell Engager LBL-051 For Autoimmune Diseases Into Clinical Development. -- Round led by Pfizer Ventures, with participation from Deep Track Capital, GV, and founding investor, Aditum Bio --
Read more
Report
Oblenio Bio Closes $62 Million Series B to Advance Tri-specific T-Cell Engager LBL-051 for Autoimmune Diseases into Clinical Development
Read more
Report
Aditum Bio & Leads Biolabs form Oblenio Bio to develop a tri-specific T-cell engager for autoimmune disorders
Aditum Bio & Leads Biolabs form Oblenio Bio to develop a tri-specific T-cell engager for autoimmune disorders
Read more
Report
Aditum Bio and Leads Biolabs Announce the Formation of Oblenio Bio to Develop a Tri-Specific T-Cell Engager for Autoimmune Disorders
Read more
Report
Aditum Bio And Leads Biolabs Announce The Formation Of Oblenio Bio To Develop A Tri-Specific T-Cell Engager For Autoimmune Disorders
Aditum Bio And Leads Biolabs Announce The Formation Of Oblenio Bio To Develop A Tri-Specific T-Cell Engager For Autoimmune Disorders. Leads Biolabs grants Oblenio Bio anexclusive option to license LBL-051, a first-in-class CD19xBCMAxCD3 tri-specific T-cel
Read more
Report
Financials
Total raised
$62M
Latest round
Series B
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series B | 2026 | $62M | Details |